SCHEMBL337692

SCHEMBL337692

COc1cc2c(O)c(C(=O)NCC(=O)OC(C)(C)C)c(=O)n(C)c2nn1

nearest known ligand 0.45

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 17/20 0.45
EGLN1 Q9GZT9 2/20 0.42
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL337712 0.87 HIF1A (0.55) HIF1AEGLN1
SCHEMBL337021 0.87 EGLN1 (0.45) HIF1AEGLN1
SCHEMBL337399 0.87 HIF1A (0.45) HIF1AEGLN1
SCHEMBL2576963 0.84 HIF1A (0.48) HIF1AEGLN1TSHR
SCHEMBL337721 0.84 EGLN1 (0.39) HIF1AEGLN1
SCHEMBL12101565 0.82 EGLN1 (0.43) HIF1AEGLN1TSHR
SCHEMBL337571 0.82 CALCA (0.41) HIF1AEGLN1
SCHEMBL2586351 0.82 HIF1A (0.42) HIF1AEGLN1TSHR
SCHEMBL336985 0.82 EGLN1 (0.48) HIF1AEGLN1TSHR
SCHEMBL2576293 0.82 EGLN1 (0.42) HIF1AEGLN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097620-B2 Diazaquinolones that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2012-01-17 US disclosed
EP-2155746-A2 DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY Amgen, Inc (US) 2010-02-24 EP disclosed
US-20090099171-A1 Diazaquinolones that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2009-04-16 US disclosed
WO-2008137084-A2 DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY AMGEN INC. (US) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099171-A1 Diazaquinolones that inhibit prolyl hydroxylase activity EGLN3, EGLN2, HIF1AN HIF1A 6/4885EGLN1 4/4885TSHR 3238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.